Calidi Biotherapeutics, Inc. (CLDI) - Form 8-K Summary
Business Context and Reporting Period
Calidi Biotherapeutics, Inc., a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on August 8, 2025. The filing serves to disclose the Company's financial results for the second quarter ended June 30, 2025, and recent corporate developments via a press release incorporated as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The 8-K acts as a notification that these results were announced in a separate press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing references "certain financial results" and "certain recent corporate developments" but does not detail specific material changes versus the prior comparable period within the text of the 8-K itself.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, or unusual items are not detailed in the provided text. The filing explicitly states that the information is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the content of the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 8, 2025) for specific Q2 2025 financial figures.
- Verify the details of the "recent corporate developments" mentioned in the press release.
- Confirm the Company's cash runway and burn rate, as these are critical for a pre-revenue or early-stage biotech firm but are absent from this summary text.
- Check for any updates on clinical trial progress or regulatory milestones referenced in the full press release.